 | • レポートコード：MRC2206A028 • 出版社/出版日：Persistence Market Research / 2022年4月15日 • レポート形態：英文、PDF、316ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Site Licence | ￥1,124,800 (USD7,600) | ▷ お問い合わせ |
| Enterprisewide | ￥1,568,800 (USD10,600) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Persistence Market Research社の本調査レポートでは、世界の初代肝細胞市場について広く調査・分析し、エグゼクティブサマリー、市場概要、主要市場動向、主要成功要因、市場背景、新型コロナウイルス感染症による危機分析、需要分析・予測、価格分析、製品別（凍結保存懸濁液肝細胞、新鮮懸濁液肝細胞、3D（スフェロイド）肝細胞、拡張肝細胞（プレーティング可能）、非特性化肝細胞）分析、種別（ヒト、ラット、マウス、イヌ、サル）分析、用途/アッセイ別（細胞生存率アッセイ、シトクロム酵素活性、高含有細胞毒性、トランスポーター阻害アッセイ、インビトロ内因性クリアランス）分析、エンドユーザー別（バイオ医薬品会社、学術・研究機関、CRO）分析、地域別分析、市場構造分析、競争分析、仮定、調査手法などの項目を掲載しております。 ・エグゼクティブサマリー ・市場概要 ・主要市場動向 ・主要成功要因 ・市場背景 ・新型コロナウイルス感染症による危機分析 ・需要分析・予測 ・価格分析 ・世界の初代肝細胞市場規模：製品別（凍結保存懸濁液肝細胞、新鮮懸濁液肝細胞、3D（スフェロイド）肝細胞、拡張肝細胞（プレーティング可能）、非特性化肝細胞） ・世界の初代肝細胞市場規模：種別（ヒト、ラット、マウス、イヌ、サル） ・世界の初代肝細胞市場規模：用途/アッセイ別（細胞生存率アッセイ、シトクロム酵素活性、高含有細胞毒性、トランスポーター阻害アッセイ、インビトロ内因性クリアランス） ・世界の初代肝細胞市場規模：エンドユーザー別（バイオ医薬品会社、学術・研究機関、CRO） ・世界の初代肝細胞市場規模：地域別 ・市場構造分析 ・競争分析 ・仮定 ・調査手法 |
Primary Hepatocytes Market – Scope of Report
The latest publication by Persistence Market Research on the global primary hepatocytes market evaluates the opportunities and current market landscape and provides detailed analysis and updates about corresponding sections affecting the market. The study offers detailed insights into current market dynamics, which include the drivers, restraints, trends, and opportunities in the market. The principal aim of the market study is to present exclusive information about how the market will perform during the forecast period of 2022-2032.
Important indicators for the successful growth of the market are presented in this comprehensive report, which includes a Year-on-Year (Y-o-Y) growth analysis of the market, and compounded annual growth rate (CAGR), which are described exhaustively in Persistence Market Research’s study. This research study can support readers to know the demand for primary hepatocytes and the quantitative development opportunities during the study period.
The research is beneficial for shareholders in the landscape, including investors, manufacturers, service providers, distributors, and suppliers, and can help them in developing suitable business strategies to flourish in the primary hepatocytes market. The insights and information presented in this persistence market research study can be leveraged by shareholders in the primary hepatocytes market, industry experts, investors, researchers, and reporters, as well as business enthusiasts.
Market statistics, as well as information linked to the macro- as well as micro-economic variables affecting the business scenario in the primary hepatocytes market, are also included in the current study. Depending on potential developments in the market, substantive insights are also encountered in this report. Additionally, by the data submitted in this report, minor companies and new entrants in the industry can be aided in making suitable company choices to achieve traction in the market.
Key Market Segments
Persistence Market Research’s study on the primary hepatocytes market offers information divided into five important segments – product, species, application/assay, end user, and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.
Product
Cryopreserved Suspension Hepatocytes
Fresh Suspension Hepatocytes
3D (Spheroid) Hepatocytes
Expanded Hepatocytes (Plateable)
Non-characterized Hepatocytes
Species
Humans
Rats
Mice
Dogs
Monkeys
Horses
Others
Application/Assay
Cell Viability Assays
Cytochrome Enzyme Activity
High Content Cytotoxicity
Transporter Inhibition Assays
In Vitro Intrinsic Clearance
Phospholipids Assays
Others
End User
Biopharmaceutical Companies
Academic and Research Institutes
Contract Research Organizations
Region
North America
Latin America
Europe
South Asia
East Asia
Oceania
MEA
Key Questions Answered in Report
Which regions will continue to remain the most profitable markets for primary hepatocytes over the coming years?
How will changing trends impact the market?
How has the COVID-19 crisis impacted market growth?
How can market players capture the low-hanging opportunities in developed regions?
What are the strategies of stakeholders in the market to shape their position in this landscape?
What are the restraining factors that investors need to be aware of and might tackle while investing in the market?
What are the developmental trends that will impact the market?
How can companies in the primary hepatocytes industry avail themselves of the growth opportunities in developed and emerging sectors?
Research Methodology
In Persistence Market Research’s study, a unique research methodology is utilized to conduct extensive research on the growth of the primary hepatocytes market, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts ensure the accuracy and reliability of the conclusions.
Secondary resources referred to by analysts during the production of the market study include statistics from governmental organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, who contributed to the development of this report as a primary resource.
Comprehensive information acquired from primary and secondary resources acts as validation from companies in the market and makes Persistence Market Research’s projections on the growth prospects of the primary hepatocytes market more accurate and reliable.
レポート目次1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusion And Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Key Inclusions
4.1. Product Adoption / Usage Analysis
4.2. Key Regulatory Scenario
4.3. PESTLE Analysis
4.4. Porters Analysis
4.5. Recent Product Launches & Approvals
4.6. Key Promotional Strategies by Manufacturers
4.7. Importance of cell-based assays in liver toxicity
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Expenditure Outlook
5.2. Forecast Factors – Relevance & Impact
5.2.1. Increasing drug discovery
5.2.2. Rapid growth in the biotechnology and biopharmaceutical industries
5.2.3. Stringent regulations for drug approvals
5.2.4. Advantages of primary cells over cell lines
5.2.5. Increasing number of biotech companies
5.3. Value Chain Analysis
5.4. Market Dynamics
5.4.1. Drivers
5.4.2. Restraints
5.4.3. Opportunity Analysis
6. COVID19 Crisis Analysis
6.1. Current COVID19 Statistics and Probable Future Impact
6.2. Current GDP Projection and Probable Impact
6.3. Current Economic Projection as compared to 2008 Economic analysis
6.4. COVID19 and Impact Analysis
6.4.1. By Product
6.4.2. By Species
6.4.3. By Application/Assay
6.4.4. By End User
6.4.5. By Region
7. Global Primary Hepatocytes Market Demand (in Volume) Analysis 2017–2021 and Forecast, 2022–2032
7.1. Historical Market (Volume) Analysis, 2017–2021
7.2. Current and Future Market (Volume) Projections, 2022–2032
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Primary Hepatocytes Market – Pricing Analysis
8.1. Country-wise & Regional Pricing Analysis by Product
8.2. Global Average Pricing Analysis Benchmark
9. Global Primary Hepatocytes Market Demand (in Value or Size in US$ Mn) Analysis 2017–2021 and Forecast, 2022–2032
9.1. Historical Market Value (US$ Mn) Analysis, 2017–2021
9.2. Current and Future Market Value (US$ Mn) Projections, 2022–2032
9.2.1. Y-o-Y Growth Trend Analysis
9.2.2. Absolute $ Opportunity Analysis
10. Global Primary Hepatocytes Market Analysis 2017–2021 and Forecast 2022–2032, By Product
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Mn) and Volume Analysis by Product, 2017–2021
10.3. Current and Future Market Size (US$ Mn) and Volume Analysis and Forecast by Product, 2022–2032
10.3.1. Cryopreserved Suspension Hepatocytes
10.3.2. Fresh Suspension Hepatocytes
10.3.3. 3D (Spheroid) hepatocytes
10.3.4. Expanded hepatocytes (plateable)
10.3.5. Non-characterized hepatocytes
10.4. Market Attractiveness Analysis by Product
11. Global Primary Hepatocytes Market Analysis 2017–2021 and Forecast 2022–2032, by Species
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Mn) Analysis by Species, 2017–2021
11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Species, 2022–2032
11.3.1. Human
11.3.2. Rat
11.3.3. Mouse
11.3.4. Dog
11.3.5. Monkey
11.3.6. Horse
11.3.7. Others
11.4. Market Attractiveness Analysis by Species
12. Global Primary Hepatocytes Market Analysis 2017–2021 and Forecast 2022–2032, by Application/Assay
12.1. Introduction / Key Findings
12.2. Historical Market Size (US$ Mn) Analysis by Application/Assay, 2017–2021
12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Application/Assay, 2022–2032
12.3.1. Cell Viability assay
12.3.2. Cytochrome enzyme activity
12.3.3. High Content Cytotoxicity
12.3.4. Transporter Inhibition Assay
12.3.5. In vitro intrinsic clearance
12.3.6. Phospholipoids Assay
12.3.7. Others
12.4. Market Attractiveness Analysis by Application/Assay
13. Global Primary Hepatocytes Market Analysis 2017–2021 and Forecast 2022–2032, by End User
13.1. Introduction / Key Findings
13.2. Historical Market Size (US$ Mn) Analysis by End User, 2017–2021
13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by End User, 2022–2032
13.3.1. Biopharmaceutical companies
13.3.2. Academic and Research institutes
13.3.3. Contract Research Organizations
13.4. Market Attractiveness Analysis by End User
14. Global Primary Hepatocytes Market Analysis 2017–2021 and Forecast 2022–2032, by Region
14.1. Introduction
14.2. Historical Market Size (US$ Mn) and Volume Analysis by Region, 2017–2021
14.3. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022–2032
14.3.1. North America
14.3.2. Latin America
14.3.3. Europe
14.3.4. East Asia
14.3.5. South Asia
14.3.6. Oceania
14.3.7. Middle East and Africa (MEA)
14.4. Market Attractiveness Analysis by Region
15. North America Primary Hepatocytes Market Analysis 2017–2021 and Forecast 2022–2032
15.1. Introduction
15.2. Pricing Analysis
15.3. Historical Market Size (US$ Mn) and Volume Analysis by Region, 2017–2021
15.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022–2032
15.4.1. By Country
15.4.1.1. U.S.
15.4.1.2. Canada
15.4.2. By Product
15.4.3. By Species
15.4.4. By Application/Assay
15.4.5. By End User
15.5. Market Attractiveness Analysis
15.5.1. By Country
15.5.2. By Product
15.5.3. By Species
15.5.4. By Application/Assay
15.5.5. By End User
15.6. Key Market Participants – Intensity Mapping
15.7. Drivers and Restraints – Impact Analysis
16. Latin America Primary Hepatocytes Market Analysis 2017–2021 and Forecast 2022–2032
16.1. Introduction
16.2. Pricing Analysis
16.3. Historical Market Size (US$ Mn) and Volume Analysis by Region, 2017–2021
16.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022–2032
16.4.1. By Country
16.4.1.1. Brazil
16.4.1.2. Mexico
16.4.1.3. Rest of Latin America
16.4.2. By Product
16.4.3. By Species
16.4.4. By Application/Assay
16.4.5. By End User
16.5. Market Attractiveness Analysis
16.5.1. By Country
16.5.2. By Product
16.5.3. By Species
16.5.4. By Application/Assay
16.5.5. By End User
16.6. Key Market Participants – Intensity Mapping
16.7. Drivers and Restraints – Impact Analysis
17. Europe Primary Hepatocytes Market Analysis 2017–2021 and Forecast 2022–2032
17.1. Introduction
17.2. Pricing Analysis
17.3. Historical Market Size (US$ Mn) and Volume Analysis by Region, 2017–2021
17.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022–2032
17.4.1. By Country
17.4.1.1. Germany
17.4.1.2. Italy
17.4.1.3. France
17.4.1.4. U.K.
17.4.1.5. Spain
17.4.1.6. BENELUX
17.4.1.7. Russia
17.4.1.8. Poland
17.4.1.9. Rest of Europe
17.4.2. By Product
17.4.3. By Species
17.4.4. By Application/Assay
17.4.5. By End User
17.5. Market Attractiveness Analysis
17.5.1. By Country
17.5.2. By Product
17.5.3. By Species
17.5.4. By Application/Assay
17.5.5. By End User
17.6. Key Market Participants – Intensity Mapping
17.7. Drivers and Restraints – Impact Analysis
18. South Asia and Pacific Primary Hepatocytes Market Analysis 2017–2021 and Forecast 2022–2032
18.1. Introduction
18.2. Pricing Analysis
18.3. Historical Market Size (US$ Mn) and Volume Analysis by Region, 2017–2021
18.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022–2032
18.4.1. By Country
18.4.1.1. India
18.4.1.2. Thailand
18.4.1.3. Indonesia
18.4.1.4. Malaysia
18.4.1.5. Rest of South Asia & Pacific
18.4.2. By Product
18.4.3. By Species
18.4.4. By Application/Assay
18.4.5. By End User
18.5. Market Attractiveness Analysis
18.5.1. By Country
18.5.2. By Product
18.5.3. By Species
18.5.4. By Application/Assay
18.5.5. By End User
18.6. Key Market Participants – Intensity Mapping
18.7. Drivers and Restraints – Impact Analysis
19. East Asia Primary Hepatocytes Market Analysis 2017–2021 and Forecast 2022–2032
19.1. Introduction
19.2. Pricing Analysis
19.3. Historical Market Size (US$ Mn) and Volume Analysis by Region, 2017–2021
19.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022–2032
19.4.1. By Country
19.4.1.1. China
19.4.1.2. Japan
19.4.1.3. South Korea
19.4.2. By Product
19.4.3. By Species
19.4.4. By Application/Assay
19.4.5. By End User
19.5. Market Attractiveness Analysis
19.5.1. By Country
19.5.2. By Product
19.5.3. By Species
19.5.4. By Application/Assay
19.5.5. By End User
19.6. Key Market Participants – Intensity Mapping
19.7. Drivers and Restraints – Impact Analysis
20. Oceania Primary Hepatocytes Market Analysis 2017–2021 and Forecast 2022–2032
20.1. Introduction
20.2. Pricing Analysis
20.3. Historical Market Size (US$ Mn) and Volume Analysis by Region, 2017–2021
20.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022–2032
20.4.1. By Country
20.4.1.1. Australia
20.4.1.2. New Zealand
20.4.2. By Product
20.4.3. By Species
20.4.4. By Application/Assay
20.4.5. By End User
20.5. Market Attractiveness Analysis
20.5.1. By Country
20.5.2. By Product
20.5.3. By Species
20.5.4. By Application/Assay
20.5.5. By End User
20.6. Key Market Participants – Intensity Mapping
20.7. Drivers and Restraints – Impact Analysis
21. Middle East and Africa Primary Hepatocytes Market Analysis 2017–2021 and Forecast 2022–2032
21.1. Introduction
21.2. Pricing Analysis
21.3. Historical Market Size (US$ Mn) and Volume Analysis by Region, 2017–2021
21.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022–2032
21.4.1. By Country
21.4.1.1. GCC Countries
21.4.1.2. Turkey
21.4.1.3. Northern Africa
21.4.1.4. South Africa
21.4.1.5. Rest of Middle East and Africa
21.4.2. By Product
21.4.3. By Species
21.4.4. By Application/Assay
21.4.5. By End User
21.5. Market Attractiveness Analysis
21.5.1. By Country
21.5.2. By Product
21.5.3. By Species
21.5.4. By Application/Assay
21.5.5. By End User
21.6. Key Market Participants – Intensity Mapping
21.7. Drivers and Restraints – Impact Analysis
22. Country Level Primary Hepatocytes Market Analysis 2022 & 2032
22.1. Introduction
22.1.1. Market Value Proportion Analysis, By Top 5 Countries
22.1.2. Global VS. Country Growth Comparison
22.2. U.S. Primary Hepatocytes Market Analysis
22.2.1. By Product
22.2.2. By Species
22.2.3. By Application/Assay
22.2.4. By End User
22.3. Canada Primary Hepatocytes Market Analysis
22.3.1. By Product
22.3.2. By Species
22.3.3. By Application/Assay
22.3.4. By End User
22.4. Mexico Primary Hepatocytes Market Analysis
22.4.1. By Product
22.4.2. By Species
22.4.3. By Application/Assay
22.4.4. By End User
22.5. Brazil Primary Hepatocytes Market Analysis
22.5.1. By Product
22.5.2. By Species
22.5.3. By Application/Assay
22.5.4. By End User
22.6. Germany Primary Hepatocytes Market Analysis
22.6.1. By Product
22.6.2. By Species
22.6.3. By Application/Assay
22.6.4. By End User
22.7. Italy Primary Hepatocytes Market Analysis
22.7.1. By Product
22.7.2. By Technology
22.7.3. By Distribution channel
22.8. France Primary Hepatocytes Market Analysis
22.8.1. By Product
22.8.2. By Species
22.8.3. By Application/Assay
22.8.4. By End User
22.9. U.K. Primary Hepatocytes Market Analysis
22.9.1. By Product
22.9.2. By Species
22.9.3. By Application/Assay
22.9.4. By End User
22.10. Spain Primary Hepatocytes Market Analysis
22.10.1. By Product
22.10.2. By Species
22.10.3. By Application/Assay
22.10.4. By End User
22.11. BENELUX Primary Hepatocytes Market Analysis
22.11.1. By Product
22.11.2. By Species
22.11.3. By Application/Assay
22.11.4. By End User
22.12. Russia Primary Hepatocytes Market Analysis
22.12.1. By Product
22.12.2. By Species
22.12.3. By Application/Assay
22.12.4. By End User
22.13. Poland Primary Hepatocytes Market Analysis
22.13.1. By Product
22.13.2. By Species
22.13.3. By Application/Assay
22.13.4. By End User
22.14. India Primary Hepatocytes Market Analysis
22.14.1. By Product
22.14.2. By Species
22.14.3. By Application/Assay
22.14.4. By End User
22.15. Thailand Primary Hepatocytes Market Analysis
22.15.1. By Product
22.15.2. By Species
22.15.3. By Application/Assay
22.15.4. By End User
22.16. Indonesia Primary Hepatocytes Market Analysis
22.16.1. By Product
22.16.2. By Species
22.16.3. By Application/Assay
22.16.4. By End User
22.17. Malaysia Primary Hepatocytes Market Analysis
22.17.1. By Product
22.17.2. By Species
22.17.3. By Application/Assay
22.17.4. By End User
22.18. China Primary Hepatocytes Market Analysis
22.18.1. By Product
22.18.2. By Species
22.18.3. By Application/Assay
22.18.4. By End User
22.19. Japan Primary Hepatocytes Market Analysis
22.19.1. By Product
22.19.2. By Species
22.19.3. By Application/Assay
22.19.4. By End User
22.20. South Korea Primary Hepatocytes Market Analysis
22.20.1. By Product
22.20.2. By Species
22.20.3. By Application/Assay
22.20.4. By End User
22.21. Australia Primary Hepatocytes Market Analysis
22.21.1. By Product
22.21.2. By Species
22.21.3. By Application/Assay
22.21.4. By End User
22.22. New Zealand Primary Hepatocytes Market Analysis
22.22.1. By Product
22.22.2. By Species
22.22.3. By Application/Assay
22.22.4. By End User
22.23. GCC Primary Hepatocytes Market Analysis
22.23.1. By Product
22.23.2. By Species
22.23.3. By Application/Assay
22.23.4. By End User
22.24. Turkey Primary Hepatocytes Market Analysis
22.24.1. By Product
22.24.2. By Species
22.24.3. By Application/Assay
22.24.4. By End User
22.25. Northern Africa Primary Hepatocytes Market Analysis
22.25.1. By Product
22.25.2. By Species
22.25.3. By Application/Assay
22.25.4. By End User
22.26. South Africa Primary Hepatocytes Market Analysis
22.26.1. By Product
22.26.2. By Species
22.26.3. By Application/Assay
22.26.4. By End User
23. Market Structure Analysis
23.1. Market Analysis by Tier of Companies
23.2. Market Share Analysis of Top Players
23.3. Market Presence Analysis
24. Competition Analysis
24.1. Competition Dashboard
24.2. Competition Benchmarking
24.3. Competition Deep Dive
24.3.1. Thermo Fisher Scientific
24.3.1.1. Overview & Key financials
24.3.1.2. Product Portfolio
24.3.1.3. Profitability by Market Segments (Product/Channel/Region)
24.3.1.4. Sales Footprint
24.3.1.5. Analysis Commentary
24.3.1.6. Strategy Overview
24.3.2. Corning Inc.
24.3.2.1. Overview & Key financials
24.3.2.2. Product Portfolio
24.3.2.3. Profitability by Market Segments (Product/Channel/Region)
24.3.2.4. Sales Footprint
24.3.2.5. Analysis Commentary
24.3.2.6. Strategy Overview
24.3.3. Lonza
24.3.3.1. Overview & Key financials
24.3.3.2. Product Portfolio
24.3.3.3. Profitability by Market Segments (Product/Channel/Region)
24.3.3.4. Sales Footprint
24.3.3.5. Analysis Commentary
24.3.3.6. Strategy Overview
24.3.4. Axol Bioscience Ltd.
24.3.4.1. Overview & Key financials
24.3.4.2. Product Portfolio
24.3.4.3. Profitability by Market Segments (Product/Channel/Region)
24.3.4.4. Sales Footprint
24.3.4.5. Analysis Commentary
24.3.4.6. Strategy Overview
24.3.5. LifeNet Health
24.3.5.1. Overview & Key financials
24.3.5.2. Product Portfolio
24.3.5.3. Profitability by Market Segments (Product/Channel/Region)
24.3.5.4. Sales Footprint
24.3.5.5. Analysis Commentary
24.3.5.6. Strategy Overview
24.3.6. SEKISUI XenoTech, LLC
24.3.6.1. Overview & Key financials
24.3.6.2. Product Portfolio
24.3.6.3. Profitability by Market Segments (Product/Channel/Region)
24.3.6.4. Sales Footprint
24.3.6.5. Analysis Commentary
24.3.6.6. Strategy Overview
24.3.7. Cytes Biotechnologies
24.3.7.1. Overview & Key financials
24.3.7.2. Product Portfolio
24.3.7.3. Profitability by Market Segments (Product/Channel/Region)
24.3.7.4. Sales Footprint
24.3.7.5. Analysis Commentary
24.3.7.6. Strategy Overview
24.3.8. Cell Biologics, Inc.
24.3.8.1. Overview & Key financials
24.3.8.2. Product Portfolio
24.3.8.3. Profitability by Market Segments (Product/Channel/Region)
24.3.8.4. Sales Footprint
24.3.8.5. Analysis Commentary
24.3.8.6. Strategy Overview
24.3.9. ZenBio, Inc.
24.3.9.1. Overview & Key financials
24.3.9.2. Product Portfolio
24.3.9.3. Profitability by Market Segments (Product/Channel/Region)
24.3.9.4. Sales Footprint
24.3.9.5. Analysis Commentary
24.3.9.6. Strategy Overview
24.3.10. BioIVT.
24.3.10.1. Overview & Key financials
24.3.10.2. Product Portfolio
24.3.10.3. Profitability by Market Segments (Product/Channel/Region)
24.3.10.4. Sales Footprint
24.3.10.5. Analysis Commentary
24.3.10.6. Strategy Overview
24.3.11. ScienCell Research Laboratories, Inc.
24.3.11.1. Overview & Key financials
24.3.11.2. Product Portfolio
24.3.11.3. Profitability by Market Segments (Product/Channel/Region)
24.3.11.4. Sales Footprint
24.3.11.5. Analysis Commentary
24.3.11.6. Strategy Overview
24.3.12. Kerafast
24.3.12.1. Overview & Key financials
24.3.12.2. Product Portfolio
24.3.12.3. Profitability by Market Segments (Product/Channel/Region)
24.3.12.4. Sales Footprint
24.3.12.5. Analysis Commentary
24.3.12.6. Strategy Overview
24.3.13. Takara Bio Inc.
24.3.13.1. Overview & Key financials
24.3.13.2. Product Portfolio
24.3.13.3. Profitability by Market Segments (Product/Channel/Region)
24.3.13.4. Sales Footprint
24.3.13.5. Analysis Commentary
24.3.13.6. Strategy Overview
24.3.14. Kosheeka
24.3.14.1. Overview & Key financials
24.3.14.2. Product Portfolio
24.3.14.3. Profitability by Market Segments (Product/Channel/Region)
24.3.14.4. Sales Footprint
24.3.14.5. Analysis Commentary
24.3.14.6. Strategy Overview
25. Assumptions and Acronyms Used
26. Research Methodology
Table 01: Global Primary Hepatocytes Market Volume (Units) Analysis 2017-2021 and Forecast 2022-2032, By ProductTable 02: Global Primary Hepatocytes Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Product
Table 03: Global Primary Hepatocytes Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Species
Table 04: Global Primary Hepatocytes Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Application / Assay
Table 05: Global Primary Hepatocytes Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By End User
Table 06: Global Primary Hepatocytes Market Volume (Units) Analysis 2017-2021 and Forecast 2022-2032, By Region
Table 07: Global Primary Hepatocytes Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Region
Table 08: North America Primary Hepatocytes Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Country
Table 09: North America Primary Hepatocytes Market Volume (Units) Analysis 2017-2021 and Forecast 2022-2032, By Product
Table 10: North America Primary Hepatocytes Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Product
Table 11: North America Primary Hepatocytes Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Species
Table 12: North America Primary Hepatocytes Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Application / Assay
Table 13: North America Primary Hepatocytes Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By End User
Table 14: Latin America Primary Hepatocytes Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Country
Table 15: Latin America Primary Hepatocytes Market Volume (Units) Analysis 2017-2021 and Forecast 2022-2032, By Product
Table 16: Latin America Primary Hepatocytes Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Product
Table 17: Latin America Primary Hepatocytes Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Species
Table 18: Latin America Primary Hepatocytes Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Application / Assay
Table 19: Latin America Primary Hepatocytes Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By End User
Table 20: Europe Primary Hepatocytes Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Country
Table 21: Europe Primary Hepatocytes Market Volume (Units) Analysis 2017-2021 and Forecast 2022-2032, By Product
Table 22: Europe Primary Hepatocytes Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Product
Table 23: Europe Primary Hepatocytes Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Species
Table 24: Europe Primary Hepatocytes Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Application / Assay
Table 25: Europe Primary Hepatocytes Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By End User
Table 26: South Asia Primary Hepatocytes Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Country
Table 27: South Asia Primary Hepatocytes Market Volume (Units) Analysis 2017-2021 and Forecast 2022-2032, By Product
Table 28: South Asia Primary Hepatocytes Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Product
Table 29: South Asia Primary Hepatocytes Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Species
Table 30: South Asia Primary Hepatocytes Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Application / Assay
Table 31: South Asia Primary Hepatocytes Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By End User
Table 32: East Asia Primary Hepatocytes Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Country
Table 33: East Asia Primary Hepatocytes Market Volume (Units) Analysis 2017-2021 and Forecast 2022-2032, By Product
Table 34: East Asia Primary Hepatocytes Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Product
Table 35: East Asia Primary Hepatocytes Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Species
Table 36: East Asia Primary Hepatocytes Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Application / Assay
Table 37: East Asia Primary Hepatocytes Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By End User
Table 38: Oceania Primary Hepatocytes Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Country
Table 39: Oceania Primary Hepatocytes Market Volume (Units) Analysis 2017-2021 and Forecast 2022-2032, By Product
Table 40: Oceania Primary Hepatocytes Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Product
Table 41: Oceania Primary Hepatocytes Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Species
Table 42: Oceania Primary Hepatocytes Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Application / Assay
Table 43: Oceania Primary Hepatocytes Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By End User
Table 44: MEA Primary Hepatocytes Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Country
Table 45: MEA Primary Hepatocytes Market Volume (Units) Analysis 2017-2021 and Forecast 2022-2032, By Product
Table 46: MEA Primary Hepatocytes Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Product
Table 47: MEA Primary Hepatocytes Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Species
Table 48: MEA Primary Hepatocytes Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Application / Assay
Table 49: MEA Primary Hepatocytes Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By End User